18 min listen
The BMJ Interview - Andrew Pollard on the Oxford/Astra Zeneca vaccine
FromThe BMJ Podcast
ratings:
Length:
45 minutes
Released:
Jan 14, 2021
Format:
Podcast episode
Description
Andrew Pollard is Director of the Oxford Vaccines Group - who, along with Astra Zeneca, have developed an modified adenovirus vaccine for SARS-CoV-2.
In this interview we talk to him about the development of that vaccine - what he thinks about the UK government's plan to increase the interval between doses; if he worries about a mutating virus and vaccine escape; and how the university came to make a deal with a commercial company to provide cost-price vaccinations for the world.
www.bmj.com/coronavirus
In this interview we talk to him about the development of that vaccine - what he thinks about the UK government's plan to increase the interval between doses; if he worries about a mutating virus and vaccine escape; and how the university came to make a deal with a commercial company to provide cost-price vaccinations for the world.
www.bmj.com/coronavirus
Released:
Jan 14, 2021
Format:
Podcast episode
Titles in the series (100)
Decriminalisation of drugs in Portugal: In 2001 Portugal abolished all criminal penalties for personal possession of drugs – effectively decriminalising their use. Health journalist Nigel Hawkes talks to João Goulão, Portugal’s drug tsar, to find out how effective this policy change has be... by The BMJ Podcast